Compare AU
Compare T3MP vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Jpmorgan Climate Chg Sol Active ETF (Managed Fund) (T3MP) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
T3MP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 82 |
Median incremental investment | $567.50 | $619.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $574.29 | $1,325.00 |
Average age group | < 26 | > 35 |
Key Summary
T3MP | CURE | |
|---|---|---|
Strategy | T3MP.AX was created on 2022-11-28 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Fund is to achieve a return through investing in equity securities of companies with exposure to the theme of climate change solutions. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Trane Technologies PLC Class A (4.66 %) Hitachi Ltd (4.59 %) Prysmian SpA (4.21 %) | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) |
Top 3 industries | Industrials (73.12 %) Utilities (26.88 %) Consumer Discretionary (9.68 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (41.52 %) France (12.60 %) Japan (7.95 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.55 % | 0.45 % |
Key Summary
T3MP | CURE | |
|---|---|---|
Issuer | JPMorgan | Global X |
Tracking index | MSCI All Country World Index - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.55 % | 0.45 % |
Price | $63.81 | $50.00 |
Size | N/A | $38.656 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.34 % | 4.24 % |
Market | ASX | ASX |
First listed date | 08/12/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
T3MP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 82 |
Median incremental investment | $567.50 | $619.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $574.29 | $1,325.00 |
Average age group | < 26 | > 35 |
Pros and Cons
T3MP | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
T3MP | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |